Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Carcinoma, Hepatocellular 37Liver Neoplasms 20Neoplasms 17Leukemia, Myeloid, Acute 13Neoplasm Metastasis 11Carcinoma, Renal Cell 9Carcinoma, Non-Small-Cell Lung 9Pancreatic Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Melanoma 7Breast Neoplasms 6Brain Neoplasms 6Unspecified Adult Solid Tumor, Protocol Specific 5Prostatic Neoplasms 5Multiple Myeloma 5Lung Neoplasms 5Kidney Neoplasms 5Recurrence 4Glioblastoma 4Colorectal Neoplasms 4Sarcoma 3Rectal Neoplasms 3Myelodysplastic Syndromes 3Leukemia, Promyelocytic, Acute 3Leukemia, Myelomonocytic, Acute 3Leukemia, Monocytic, Acute 3Leukemia, Megakaryoblastic, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia, Erythroblastic, Acute 3Leukemia, Eosinophilic, Acute 3

Interventions

Melphalan 4Irinotecan 4Filgrastim 4Cyclophosphamide 4Busulfan 4fludarabine 3Topotecan 3Temozolomide 3Granulocyte Colony-Stimulating Factor 3pegfilgrastim 2liposomal doxorubicin 2Thiotepa 2Sirolimus 2Peripheral Blood Stem Cell Transplantation 2Doxorubicin 2Bone Marrow Transplantation 2trioctyl phosphine oxide 1ribociclib 1regorafenib 1poly ICLC 1pembrolizumab 1pegylated granulocyte colony-stimulating factor 1omburtamab I-131 1olaparib 1mocetinostat 1lexatumumab 1irinotecan sucrosofate 1fludarabine phosphate 1cixutumumab 1ceritinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Rhabdomyosarcoma × Sorafenib × Clear all
NCT01518413 2015-02-27

Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors

Children's National Research Institute

Phase 1 Completed
17 enrolled
CNSSarcoma

Brain Neoplasms, Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡